Sage Journals: Discover world-class research

Abstract

Beta-interferon (beta-IFN) has a proven treatment effect on relapsing-remitting multiple sclerosis (MS), presumably through its regulatory properties on T-cell activation and cytokine production. This paper examines whether combination therapy of beta-IFN with prednisone would enhance immunoregulatory effects of beta-IFN by measuring serum levels of selected proinflammatory cytokines and soluble T-cell activation markers associated with MS. The selected markers were analyzed in MS patients treated with beta-IFN alone (n-22) and beta-IFN combined with a low daily dose of prednisone (n-33), as compared with those in 27 healthy controls at baseline and at a three-month interval for one year. The study confirmed that beta-IFN treatment inhibited serum levels of tumor necro sis factor-alpha (TNFa) and intracellular adhesion molecule-1 (IC A M-1) in patients with MS. However, combination therapy did not significantly enhance the inhibitory effect of beta-IFN treatment on the production of TNFa, interleukin (IL)-12, IL-2R, and IC A M-1, while the addition of prednisone antagonized the effect of beta-IFN on up-regulation of IL-10 and soluble C D95. No difference in the occurrence of binding antibodies to beta-IFN was found between the two treatment groups. The findings are important for the understanding of the role of combination therapy in the treatment of MS.

Keywords

beta-interferon cytokines multiple sclerosis T cells

Get full access to this article

View all access options for this article.

References

Martin R , McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis . Crit Rev Clin Lab Sci 1995; 32: 121-182 .

Navikas V , Link H. Cytokines and the pathogenesis of multiple sclerosis . J Neurosci Res 1996; 45: 322-333 .

Olsson T. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis . Immunol Rev 1995; 144: 245-268 .

Hartung HP et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging . Ann Neurol 1995; 38: 186-193 .

Zang YC et al. Immunoregulation and blocking antibodies induced by interferon beta treatment in MS . Neurology 2000; 55: 397-404 .

Rep MH et al. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients . J Neuroimmunol 1999; 96: 92-100 .

Rudick RA et al. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis . Neurology 1998; 50: 1294-1300 .

Rott O et al. Interleukin-10 prevents experimental allergic encephalomyelitis in rats . Eur J Immunol 1994; 24: 1434-1440 .

Zipp F et al. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis . Ann Neurol 1998; 43: 116-120 .

Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis

Abstract

Keywords

Get full access to this article

References